Publication & Citation Trends
Publications
0 total
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial OA
Cited by 225
Semantic Scholar
Results of the first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with mild Alzheimer’s disease
Cited by 11
Semantic Scholar
PreSERVE-AMINovelty and Significance OA
Cited by 40
Semantic Scholar
Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study OA
Cited by 49
Semantic Scholar
The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. OA
Cited by 113
Semantic Scholar
Abstract 12754: Infused CD34 Cell Dose, not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients With Left Ventricular Dysfunction post STEMI: Results of the PreSERVE-AMI Trial
Cited by 0
Semantic Scholar
ONE YEAR FOLLOW-UP RESULTS FROM PRESERVE-AMI: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF INTRACORONARY INFUSION OF AUTOLOGOUS CD34+ CELLS IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION POST STEMI OA
Cited by 2
Semantic Scholar
Abstract 17457: PreSERVE-AMI: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients with Left Ventricular Dysfunction Post STEMI
Cited by 102
Semantic Scholar
Research Topics
Alzheimer's disease research and treatments
(7)
Mesenchymal stem cell research
(5)
Blood Coagulation and Thrombosis Mechanisms
(5)
Angiogenesis and VEGF in Cancer
(4)
Cholinesterase and Neurodegenerative Diseases
(4)
Affiliations
Amgen (United States)
Emory University
Vanderbilt University
Ionis Pharmaceuticals (United States)
University of Florida